

1/1 - (C) WPI / DERWENT

AN - 2002-269525 [31]

AP - EP20010984565 20010117; WO2001US01384 20010117; IBased on WO0218412 I
; AU20010029503 20010117

PR - US20010259516P 20010104; US20000228086P 20000828

TI - Seventeen nucleic acid molecules encoding human secreted proteins,
useful in the prevention, treatment and diagnosis of cancer, immune
disorders, cardiovascular disorders and neurological diseases

IW - SEVENTEEN NUCLEIC ACID MOLECULAR ENCODE HUMAN SECRETION PROTEIN USEFUL
PREVENT TREAT DIAGNOSE CANCER IMMUNE DISORDER CARDIOVASCULAR DISORDER
NEUROLOGICAL DISEASE

PA - (HUMA-N) HUMAN GENOME SCI INC

PN - EP1317472 A1 20030611 DW200346 C07H21/04 Eng 000pp

- WO0218412A1 20020307 DW200231 C07H21/04 Eng 501pp

- AU200129503 A 20020313 DW200249 C07H21/04 000pp

IC - C07H5/00 ; C07H21/02 ; C07H21/04 ; C07K14/00 ; C12N1/21 ; C12N15/63 ;
C12N15/85 ; C12N15/86 ; C12Q1/68

AB - WO200218412 NOVELTY - Seventeen nucleic acid molecules encoding human
secreted proteins, are new.

- DETAILED DESCRIPTION - Seventeen nucleic acid molecules encoding human
secreted proteins, are new.

- Each nucleic acid molecule (S1) comprises a sequence which is at least
95% identical to a sequence selected from:

- (a) a polynucleotide fragment of one of the 49 nucleotide sequences
(N1) defined in the specification, or a polynucleotide fragment of the
cDNA sequence (C1) included in one of the ATCC Deposit Nos. defined in
the specification, where C1 is hybridizable to a nucleotide sequence
selected from N1;
 - (b) a polynucleotide encoding a polypeptide fragment, domain or
epitope of one of the 49 polypeptide sequences (P1) defined in the
specification, or a polypeptide fragment, domain or epitope encoded by
C1;
 - (c) C1 or a polynucleotide encoding a polypeptide selected from P1;
 - (d) a polynucleotide which is a variant, preferably allelic variant,
of a sequence selected from N1;
 - (e) a polynucleotide which encodes a species homolog of a sequence
selected from P1; or
 - (f) a polynucleotide capable of hybridizing under stringent conditions
to any of the polynucleotides of (a) to (e), where the polynucleotide
does not hybridize under stringent conditions to a nucleic acid having
a sequence of only A or T residues.
- INDEPENDENT CLAIMS are also included for the following:
- (1) a recombinant vector comprising S1;
 - (2) a method of making a recombinant host cell comprising S1;
 - (3) a recombinant host cell, comprising vector sequences, produced by
the method of (2);
 - (4) an isolated polypeptide (P2), comprising an amino acid sequence at
least 95% identical to a sequence selected from:
 - (a) a polypeptide fragment, domain or epitope of a sequence selected
from P1 or from the sequence encoded by C1, where the polypeptide
fragment may have biological activity;
 - (b) a secreted form of a protein selected from P1 or from the sequence

- encoded by C1;
- (c) a full length protein selected from P1 or from the sequence encoded by C1;
- (d) a variant, preferably allelic variant, of a sequence selected from P1; or
- (e) a species homologue of a sequence selected from P1;
- (5) an isolated antibody that specifically binds to P2;
- (6) a recombinant host cell that expresses P2;
- (7) a method of making a polypeptide, comprising culturing the recombinant host cell of (6);
- (8) the polypeptide produced by the method of (7);
- (9) a method of preventing, treating or ameliorating a medical condition, comprising administering P2 or S1;
- (10) a method of diagnosing a pathological condition or a susceptibility to a pathological condition, comprising:
 - (a) determining the presence or absence of a mutation in S1; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation;
- (11) a method of diagnosing a pathological condition or a susceptibility to a pathological condition, comprising:
 - (a) determining the presence or amount of expression of P2 in a biological sample; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide;
- (12) a method of identifying a binding partner to P2, comprising:
 - (a) contacting P2 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide;
- (13) the gene corresponding to a cDNA sequence encoding a polypeptide selected from P1;
- (14) a method of identifying an activity in a biological assay, comprising:
 - (a) expressing a sequence selected from S1 in a cell;
 - (b) isolating the supernatant;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity; and
- (15) the product produced by the method of (14).
- **ACTIVITY** - Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic; cardiant.
- **Chick chorioallantoic membrane (CAM)** is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of the polypeptides to stimulate angiogenesis in CAM can be examined.
- **Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*)** are incubated at 37.8 degrees Centigrade and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods. On Day 4 of development, a window is made into the egg shell of chick

eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope (Wild M8) and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

- **MECHANISM OF ACTION - Gene therapy.**
- **USE - The polynucleotides and polypeptides are useful for preventing, treating or ameliorating a medical condition (claimed) in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep.**
- **The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities.**
- **The polynucleotide are useful for chromosome identification. The nucleic acids, protein, antibodies, agonists and antagonists are useful in the diagnosis, treatment and prevention of:**
 - **(a) cancer, particularly breast and ovarian cancer, and other cancers of the adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver, lung, or urogenital;**
 - **(b) immune disorders such as Addison's disease, allergies, autoimmune hemolytic anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis;**
 - **(c) cardiovascular disorders such as myocardial ischemias;**
 - **(d) wound healing;**
 - **(e) neurological diseases such as cerebral anoxia and epilepsy; and**
 - **(f) infectious diseases such as viral, bacterial, fungal and parasitic infections.**
- **Numerous examples of each type of disorder are given in the specification.**
- **(Dwg.0/0)**

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN ***402537-39-7*** REGISTRY
 CN DNA (human clone HTPIY88 305-amino acid secretory protein cDNA plus
 flanks) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 47: PN: WO0218412 SEQID: 52 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 1837
 NA 481 a 476 c 447 g 433 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2002018412
	claimed
	SEQID 52

```

SEQ      1  ggcacgagca gaaagcaacc tcagctgaaa caaatgcata attataattt
      51  gatttcagaa gtggaaacat gacccgaatt catgcaccta ctgattactc
     101  caaattcctt tattgttgaa gctggagcag aagtgggggt ccaccgtgga
     151  agtaaggaaa agcaaaacag aacaggggtc tcatccaggg agccatgtcg
     201  atggctatgg ggagctccac cttgctcttg ggggtggggc ctggccctgg
     251  gtgggactgt ggggtgatga gggttgtgct atgctggcta cctgggtgga
     301  attgccaagg agagagcagc acgtagatcc tccctgtcat caggcagagc
     351  tcttcagtga ggtgggctca gggagggtc tgtgcctctg ttcagcagag
     401  ctgcagctgc tgcccagctc tcaggaggca agctggactc cctcactcag
     451  ctgcaggagc aaggacagtg aggtcacaac ccgctgagc catgccagcc
     501  aacttcacag agggcagctt cgattccagt gggaccgggc agacgctgga
     551  ttcttcccca gtggcttgca ctgaaacagt gacttttact gaagtgggtg
     601  aaggaaagga atggggttcc ttctactact cctttaagac tgagcaattg
     651  ataactctgt gggctcctct tgtttttacc attgttgaa actccgttgt
     701  gcttttttcc acatggagga gaaagaagaa gtcaagaatg accttctttg
     751  tgactcagct ggccatcaca gaaaagcaag ccagggtcct cattgtgatc
     801  gcctggagcc tgtcttttct gttctccatt cccaccctga tcatatttgg
     851  gaagaggaca ctgtccaacg gtgaagtgca gtgctgggcc ctgtggcctg
     901  acgactccta ctggacccca tacatgacca tcgtggcctt cctggtgtac
     951  ttcateccctc tgacaatcat cagcatcatg tatggcattg tgatccgaac
    1001  tatttggaatt aaaagcaaaa cctacgaaac agtgatttcc aactgctcag
    1051  atgggaaact gtgcagcagc tataaccgag gactcatctc aaaggcaaaa
    1101  atcaaggcta tcaagtatag catcatcatc attcttgctt tcatctgctg
    1151  ttggagtcca tacttcctgt ttgacatttt ggacaatttc aacctccttc
    1201  cagacaccca ggagcgtttc tatgcctctg tgatcattca gaacctgcca
    1251  gcattgaata gtgccatcaa cccctcatc tactgtgtct tcagcagctc
    1301  catctctttc cctgcaggg agcaaagatc acaggattcc agaatgacgt
    1351  tccgggagag aactgagagg catgagatgc agattctgtc caagccagaa
    1401  ttcactctaga ccctagggca gtgccagtgc taggctgagc accatcagct
    1451  ctcccagggtc cttgtcacct gcttggggcac gtgcatggaa cccgagccaa
    1501  cttcacccca cctcgtcat tacctgggag atgcacaaga caaatgttct
    1551  aatgactgca tgcactgctt aagtattggc caacacgaac tccccagtta
    1601  ttcatgccag ccaggaagga aacgccttcc ttccccacca tccccagccc
    1651  tccttcccac tggccagcac ctgaacccag tgaacacagg catcagtggg
    1701  ccagggtcct ggcttggagc cagtgagtag acaggcaagc agaggggaca
    1751  aaggtagctg ggttatacat gaatattctc attacaatag aagaaaataa
    1801  aagacttaat taagcccaaa aaaaaaaaaa aaaaaaa

```

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/539565
17 JUN 2005

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN ***402537-11-5*** REGISTRY
 CN DNA (human clone HTPIY88 43-amino acid secretory peptide cDNA plus flanks)
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 23: PN: WO0218412 SEQID: 24 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 1872

NA 482 a 484 c 458 g 439 t 1 k 2 n 4 w 2 y

PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source | Reference

=====+=====

Not Given | WO2002018412

| claimed

| SEQID 24

```

SEQ      1 gcagaaagca acctcagctg aaacaaatgc ataattataa tttgatttca
      51 gaagtggaaa catgaccgca attcatgcac ctactgatta ctccaaattc
     101 ctttattgtt gaagctggag cagaagtggg ggtccaccgt ggaagtaagg
     151 aaaagcaaaa cagaacaggg gtctcatcca gggagccatg tcgatggcta
     201 tggggagctc caccttgctc ttgggggtggg gccctggccc tgggtgggac
     251 tgtggggtga tgagggttgt gctatgctgg ctacctggtg gtaattgcca
     301 aggagagagc agcacgtaga tcctccctgt catcaggcag agctcttcag
     351 tgaggtgggc tcagggaggg ctctgtgcct ctgttcagca gagctgcagc
     401 tgctgcccag ctctcaggag gcaagctgga ctccctcact cagctgcagg
     451 agcaaggaca gtgaggctca accccgctg agccatgcca gccaaacttca
     501 cagagggcag cttcgattcc agtgggaccg ggcagacgct ggattcttcc
     551 ccagtggcct gcaactgaaac agtgactttt actgaagtgg tggaggaaa
     601 ggaatggggt tccttctact actcctttaa gactgagcaa ttgataactc
     651 tgtgggtcct ctttgttttt accattgttg gaaactccgt tgtgctttt
     701 tccacatgga ggagaaagaa gaagtcaaga atgaccttct ttgtgactca
     751 gctggccatc acagaaaagc aagccagggt cctcattgtg atcgccgtga
     801 gcctgtcttt tctgttctcc attcccaccc tgatcatatt tgggaagagg
     851 acactgtcca acggtgaagt gcagtgtgtg gccctgtggc ctgacgactc
     901 ctactggacc ccatacatga ccatcgtggc cttcctggtg tacttcatcc
     951 ctctgacaat catcagcatc atgtatggca ttgtgatccg aactatttgg
    1001 attaaaagca aaacctacga aacagtgatt tccaactgct cagatgggaa
    1051 actgtgcagc agctataacc gaggactcwt ytywwwkgca aaaatcaagg
    1101 ctatcaagta tagcatcatc atcattcttg cttcatctg ctggtggagt
    1151 ccatacttcc tgtttgacat tttggacaat ttcaacctcc ttccagacac
    1201 ccaggagcgt ttctatgcct ctgtgatcat tcagaacctg ccagcattga
    1251 atagtggcat caacccctc atctactgtg tcttcagcag ctccatctct
    1301 ttcccttgca gggagcaaa atcacaggat tccagaatga cgttccggga
    1351 gagaactgag aggcattgag tgcagattct gtccaagcca gaattcatct
    1401 agaccctagg gcagtgccag tgctaggctg agcaccatca gctctcccag
    1451 gtccttgtea cctgcttggg cacgtgcatg gaacccgagc caacttcacc
    1501 ccaccctcgt cattacctgg gagatgcaca agacaaatgt tctaagtact
    1551 gcatgcactg cttaagtatt ggccaacacg aactccccag ttattcatgc
    1601 cagccaggaa ggaaacgcct tccttcccca ccattcccag cctccttcc
    1651 cactggccag cacctgaacc cagtgaacac aggcattcag ggtccagggt
    1701 cctggcttgg agccagttag tagacaggca agcagagggg acaaaggtag
    1751 ctgggttata catgaatatt ctctattaca tagaagaaaa taaaagactt
    1801 aattaagccc aaaaaaaaaa aaaaaaaaaa ctcgaggggg ggcccggacc
    1851 caattcgccc tatagtagn ng

```

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

(402537-39-7) DNA (human clone HTPIY88 305-amino acid secretory protein
cDNA plus flanks)
Length = 1837 Score = 2698 Expect = 0.0

```

Score = 2698    Expect = 0.0
Identities = 1367/1369 (99%)
Strand = Plus / Plus
Query:      1 gggctcagggagggctctgtgcctccgttcagcagagctgcagctgctgccagc
55
Subject:    364 gggctcagggagggctctgtgcctctgttcagcagagctgcagctgctgccagc
418
Query:      56 tctcaggaggcaagctggactccctcactcagctgcaggagcaaggacagtgagg
110
Subject:    419 tctcaggaggcaagctggactccctcactcagctgcaggagcaaggacagtgagg
473
Query:     111 ctcaaccccgctgagccatgccagccaacttcacagagggcagcttcgattcca
165
Subject:    474 ctcaaccccgctgagccatgccagccaacttcacagagggcagcttcgattcca
528
Query:     166 gtgggaccgggcagacgctggattcttccccagtggttgactgaaacagtgac
220
Subject:    529 gtgggaccgggcagacgctggattcttccccagtggttgactgaaacagtgac
583
Query:     221 ttttactgaagtgggtggaaggaaaggaatggggttccttctactactcctttaag
275
Subject:    584 ttttactgaagtgggtggaaggaaaggaatggggttccttctactactcctttaag
638
Query:     276 actgagcaattgataactctgtgggtcctctttgtttttaccattgttggaact
330
Subject:    639 actgagcaattgataactctgtgggtcctctttgtttttaccattgttggaact
693
Query:     331 ccgttgctgtctttttccacatggaggagaaagaagaagtcaagaatgaccttctt
385
Subject:    694 ccgttgctgtctttttccacatggaggagaaagaagaagtcaagaatgaccttctt
748
Query:     386 tgtgactcagctggccatcacagaaaagcaagccagggtcctcattgtgatcgcc
440
Subject:    749 tgtgactcagctggccatcacagaaaagcaagccagggtcctcattgtgatcgcc
803
Query:     441 tggagcctgtctttttctgttctccattcccaccctgatcatatttggaagagga
495
Subject:    804 tggagcctgtctttttctgttctccattcccaccctgatcatatttggaagagga
858
```

Query: 496 cactgtccaacggtgaagtgcagtgctgggccctgtggcctgacgactcctactg
 550
 Subject: 859 cactgtccaacggtgaagtgcagtgctgggccctgtggcctgacgactcctactg
 913

Query: 551 gaccccatacatgaccatcgtggccttcctgggtgtacttcacccctctgacaatc
 605
 Subject: 914 gaccccatacatgaccatcgtggccttcctgggtgtacttcacccctctgacaatc
 968

Query: 606 atcagcatcatgtatggcattgtgatccgaactatttggattaaaagcaaacct
 660
 Subject: 969 atcagcatcatgtatggcattgtgatccgaactatttggattaaaagcaaacct
 1023

Query: 661 acgaaacagtgatttccaactgctcagatgggaaactgtgcagcagctataaccg
 715
 Subject: 1024 acgaaacagtgatttccaactgctcagatgggaaactgtgcagcagctataaccg
 1078

Query: 716 aggactcatctcaaaggcaaaaatcaaggctatcaagtatagcatcatcatcatt
 770
 Subject: 1079 aggactcatctcaaaggcaaaaatcaaggctatcaagtatagcatcatcatcatt
 1133

Query: 771 cttgccttcacatctgctggtggagtcatacttcctggttgacattttggacaatt
 825
 Subject: 1134 cttgccttcacatctgctggtggagtcatacttcctggttgacattttggacaatt
 1188

Query: 826 tcaacctccttcagacacccaggagcggtttctatgcctctgtgatcattcagaa
 880
 Subject: 1189 tcaacctccttcagacacccaggagcggtttctatgcctctgtgatcattcagaa
 1243

Query: 881 cctgccagcattgaatagtgccatcaacccccctcatctactgtgtcttcagcagc
 935
 Subject: 1244 cctgccagcattgaatagtgccatcaacccccctcatctactgtgtcttcagcagc
 1298

Query: 936 tccatctctttccctgcagggagcaaagatcacaggattccagaatgacgttcc
 990
 Subject: 1299 tccatctctttccctgcagggagcaaagatcacaggattccagaatgacgttcc
 1353

Query: 991 gggagagaactgagaggcatgagatgcagattctgtccaagccagaattcatcta
 1045
 Subject: 1354 gggagagaactgagaggcatgagatgcagattctgtccaagccagaattcatcta
 1408

Query: 1046 gaccctagggcagtgccagtgctaggctgagcaccatcagctctcccaggtcctt
1100

|||||
Subject: 1409 gaccctagggcagtgccagtgctaggctgagcaccatcagctctcccaggtcctt
1463

Query: 1101 gtcacctgcttgggcacgtgcatggaacccgagccaacttcacccaccctcgtc
1155

|||||
Subject: 1464 gtcacctgcttgggcacgtgcatggaacccgagccaacttcacccaccctcgtc
1518

Query: 1156 attacctgggagatgcacaagacaaatgttctaatactgcatgcactgcttaag
1210

|||||
Subject: 1519 attacctgggagatgcacaagacaaatgttctaatactgcatgcactgcttaag
1573

Query: 1211 tattggccaacacgaactccccagttattcatgccagccaggaaggaaacgcctt
1265

|||||
Subject: 1574 tattggccaacacgaactccccagttattcatgccagccaggaaggaaacgcctt
1628

Query: 1266 ccttccccaccattcccagccctccttcccactggccagcacctgaacccagtga
1320

|||||
Subject: 1629 ccttccccaccattcccagccctccttcccactggccagcacctgaacccagtga
1683

Query: 1321 acacaggcattagtgggtccagggctcctggcttgagccagtgagtagac 1369

|||||
Subject: 1684 acacaggcatcagtgggtccagggctcctggcttgagccagtgagtagac 1732

(402537-11-5) DNA (human clone HTPIY88 43-amino acid secretory peptide cDNA
plus flanks)

Length = 1872 Score = 2670 Expect = 0.0

Score = 2670 Expect = 0.0
Identities = 1360/1369 (99%)
Strand = Plus / Plus

Query: 1 gggctcagggagggctctgtgcctccgttcagcagagctgcagctgctgccagc
55

|||||
Subject: 357 gggctcagggagggctctgtgcctctgttcagcagagctgcagctgctgccagc
411

Query: 56 tctcaggaggcaagctggactccctcactcagctgcaggagcaaggacagtgagg
110

|||||
Subject: 412 tctcaggaggcaagctggactccctcactcagctgcaggagcaaggacagtgagg
466

Query: 111 ctcaaccccgctgagccatgccagccaacttcacagagggcagcttcgattcca
165

|||||
Subject: 467 ctcaaccccgctgagccatgccagccaacttcacagagggcagcttcgattcca
521

Query: 166 gtgggaccgggcagacgctggattcttccccagtggttgactgaaacagtgac
 220
 Subject: 522 gtgggaccgggcagacgctggattcttccccagtggttgactgaaacagtgac
 576
 Query: 221 ttttactgaagtgggtggaaggaaaggaatgggggttccttctactactcctttaag
 275
 Subject: 577 ttttactgaagtgggtggaaggaaaggaatgggggttccttctactactcctttaag
 631
 Query: 276 actgagcaattgataactctgtgggtcctctttgtttttaccattggttgaaact
 330
 Subject: 632 actgagcaattgataactctgtgggtcctctttgtttttaccattggttgaaact
 686
 Query: 331 ccgttgtgcttttttccacatggaggagaaagaagaagtcaagaatgaccttctt
 385
 Subject: 687 ccgttgtgcttttttccacatggaggagaaagaagaagtcaagaatgaccttctt
 741
 Query: 386 tgtgactcagctggccatcacagaaaagcaagccagggtcctcattgtgatcgcc
 440
 Subject: 742 tgtgactcagctggccatcacagaaaagcaagccagggtcctcattgtgatcgcc
 796
 Query: 441 tggagcctgtcttttctgttctccattcccaccctgatcatatttggaagagga
 495
 Subject: 797 tggagcctgtcttttctgttctccattcccaccctgatcatatttggaagagga
 851
 Query: 496 cactgtccaacggtgaagtgcagtgctgggccctgtggcctgacgactcctactg
 550
 Subject: 852 cactgtccaacggtgaagtgcagtgctgggccctgtggcctgacgactcctactg
 906
 Query: 551 gaccccatacatgaccatcgtggccttccctgggtgtacttcatccctctgacaatc
 605
 Subject: 907 gaccccatacatgaccatcgtggccttccctgggtgtacttcatccctctgacaatc
 961
 Query: 606 atcagcatcatgtatggcattgtgatccgaactatttgattaaaagcaaaacct
 660
 Subject: 962 atcagcatcatgtatggcattgtgatccgaactatttgattaaaagcaaaacct
 1016
 Query: 661 acgaaacagtgatttccaactgctcagatgggaaactgtgcagcagctataaccg
 715
 Subject: 1017 acgaaacagtgatttccaactgctcagatgggaaactgtgcagcagctataaccg
 1071

/ Query: 716 aggactcatctcaaaggcaaaaatcaaggctatcaagtatagcatcatcatcatt
 770
 Subject: 1072 aggactcwtytywwwkgcaaaaatcaaggctatcaagtatagcatcatcatcatt
 1126
 Query: 771 cttgccttcatctgctggttgaggtccatacttctggttgacattttggacaatt
 825
 Subject: 1127 cttgccttcatctgctggttgaggtccatacttctggttgacattttggacaatt
 1181
 Query: 826 tcaacctccttccagacacccaggagcggtttctatgcctctgtgatcattcagaa
 880
 Subject: 1182 tcaacctccttccagacacccaggagcggtttctatgcctctgtgatcattcagaa
 1236
 Query: 881 cctgccagcattgaatagtgccatcaacccccctcatctactgtgtcttcagcagc
 935
 Subject: 1237 cctgccagcattgaatagtgccatcaacccccctcatctactgtgtcttcagcagc
 1291
 Query: 936 tccatctctttccctgcagggagcaaagatcacaggattccagaatgacgttcc
 990
 Subject: 1292 tccatctctttccctgcagggagcaaagatcacaggattccagaatgacgttcc
 1346
 Query: 991 gggagagaactgagaggcatgagatgcagattctgtccaagccagaattcatcta
 1045
 Subject: 1347 gggagagaactgagaggcatgagatgcagattctgtccaagccagaattcatcta
 1401
 Query: 1046 gaccctagggcagtgccagtgctaggctgagcaccatcagctctcccaggtcctt
 1100
 Subject: 1402 gaccctagggcagtgccagtgctaggctgagcaccatcagctctcccaggtcctt
 1456
 Query: 1101 gtcacctgcttgggcacgtgcatggaacccgagccaacttcaccccaccctcgtc
 1155
 Subject: 1457 gtcacctgcttgggcacgtgcatggaacccgagccaacttcaccccaccctcgtc
 1511
 Query: 1156 attacctgggagatgcacaagacaaatgttctaatactgcatgcactgcttaag
 1210
 Subject: 1512 attacctgggagatgcacaagacaaatgttctaatactgcatgcactgcttaag
 1566
 Query: 1211 tattggccaacacgaactccccagttattcatgccagccaggaaggaaacgcctt
 1265
 Subject: 1567 tattggccaacacgaactccccagttattcatgccagccaggaaggaaacgcctt
 1621

Query: 1266 ccttccccaccattcccagccctccttcccactggccagcacctgaacccagtga
1320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject: 1622 ccttccccaccattcccagccctccttcccactggccagcacctgaacccagtga
1676

Query: 1321 acacaggcattagtggtccagggtcctggcttggagccagtgagtagac 1369
||||||||| ||||||||||||||||||||||||||||||||||
Subject: 1677 acacaggcatcagtggtccagggtcctggcttggagccagtgagtagac 1725